Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

355 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term efficacy and safety of etravirine-containing regimens in a real-life cohort of treatment-experienced HIV-1-infected patients.
Allavena C, Katlama C, Cotte L, Roger PM, Delobel P, Cheret A, Duvivier C, Poizot-Martin I, Hoen B, Cabie A, Cheret A, Lahoulou R, Raffi F, Pugliese P; Dat’AIDS Study group. Allavena C, et al. Infect Dis (Lond). 2016;48(5):392-8. doi: 10.3109/23744235.2015.1133927. Epub 2016 Jan 13. Infect Dis (Lond). 2016. PMID: 26757613 Clinical Trial.
Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial.
Molina JM, Journot V, Morand-Joubert L, Yéni P, Rozenbaum W, Rancinan C, Fournier S, Morlat P, Palmer P, Dupont B, Goujard C, Dellamonica P, Collin F, Poizot-Martin I, Chene G; ALIZE (Agence Nationale de Recherches sur le SIDA 099) Study Team. Molina JM, et al. J Infect Dis. 2005 Mar 15;191(6):830-9. doi: 10.1086/428091. Epub 2005 Feb 10. J Infect Dis. 2005. PMID: 15717256 Clinical Trial.
Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients.
Allavena C, Ferré V, Brunet-François C, Delfraissy JF, Lafeuillade A, Valantin MA, Bentata M, Michelet C, Poizot-Martin I, Dailly E, Launay O, Raffi F; Bitherapy Kaletra-Sustiva Study Group. Allavena C, et al. J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):300-6. doi: 10.1097/01.qai.0000165914.42827.bb. J Acquir Immune Defic Syndr. 2005. PMID: 15980689 Clinical Trial.
[The Nadis cohort: 6236 HIV-infected patients followed up in French university hospitals].
Agher R, Duvivier C, Katlama C, Gérard Y, Yazdanpanah Y, Billaud E, Jovelin T, Raffi F, Enel P, Poizot-Martin I, Puglièse P, Dellamonica P, Barone M, Cuzin L, Marchou B; Groupe Nadis. Agher R, et al. Med Mal Infect. 2005 Jul-Aug;35(7-8):407-10. doi: 10.1016/j.medmal.2005.06.004. Med Mal Infect. 2005. PMID: 16139459 French.
355 results